Emerging agents for the treatment of Chagas disease: what is in the preclinical and clinical development pipeline?

Chagas disease treatment relies on the lengthy administration of benznidazole and/or nifurtimox, which have frequent toxicity associated. The disease, caused by the parasiteWe provide an updated view of the path to achieve the aforementioned goal. From state-of-the-artIn addition to the necessary research on new drugs and much awaited biomarkers of treatment efficacy, a key step will be to generalize access to diagnosis and treatment and maximize efforts to impede transmission.